20374 Seneca Meadows Parkway
About Intrexon Corporation
Through the engineering of biology, Intrexon is helping to address some of the world’s most pressing challenges and is working with industry and government leaders to realize a better, healthier planet. Today our platform is delivering new therapies in health, supplying unique solutions to address global energy demand, developing unparalleled features and productivity advancements in food, creating innovative applications for consumers, and helping to restore and protect the environment.
To execute on its mission, Intrexon has integrated a suite of technologies and expertise across a number of cellular systems to drive development and commercialization of bio-based solutions. Our solutions include: Friendly™ Aedes mosquitoes genetically engineered to suppress the invasive Aedes aegypti mosquito; Arctic® apples that will not brown when bitten, sliced, or bruised; a clinically validated transcriptional gene switch to precisely control production of biotherapeutics; bovine reproductive technologies driving genetic gain for the dairy and beef industries; genetically engineered miniature swine models to provide better predictive efficacy in evaluation of new medicines; and our AquAdvantage® salmon bringing productivity benefits to the aquaculture industry through our majority-owned subsidiary AquaBounty. Intrexon’s cutting-edge platforms have broad applicability, thus opening the door to the considerable potential of engineered biology.
Intrexon and our collaborators are building solutions to challenging issues across fields as diverse as medicine, fuel, agriculture, nutrition, personal care, chemicals, and manufacturing, forging a sustainable path forward for current and future generations. We call our approach Better DNA® and invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook and LinkedIn.
231 articles with Intrexon Corporation
Precigen Announces Clearance of IND to Initiate Phase 1 Study for First-in-Class PRGN-3005 UltraCAR-T™ to Treat Advanced Stage Platinum Resistant Ovarian Cancer Patients
First-in-class therapy using autologous CAR-T cells targeting advanced ovarian cancer
Intrexon Partners with Next Green Wave to Advance Intrexon's Botticelli™ Next Generation Plant Propagation Platform into Development for Cannabis
Companies to apply Intrexon's proprietary Botticelli™ platform toward rapid and sustainable cannabis plantlet production
Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that the company and its subsidiaries will present at upcoming investor conferences in San Francisco.
- Executive leadership to discuss recent announcements
Agreement enables Merck KGaA, Darmstadt, Germany, to maintain an investment in the rapidly advancing oncology field of CAR-T, while focusing its R&D efforts
Intrexon and Merck KGaA, Darmstadt, Germany, Announce Agreement Realizing Precigen's Vision for Full Developmental Autonomy of its CAR-T Program
Merck KGaA, Darmstadt, Germany, to assign its Chimeric Antigen Receptor T-cell (CAR-T) rights to Intrexon
Intrexon and AquaBounty Receive Regulatory Exemption in Development of Gene Edited Tilapia for More Sustainable Production
Assessment by Argentina's National Advisory Commission on Agricultural Biotechnology Sets Regulatory Precedent
Quarterly GAAP revenues of $32.4 million and net loss attributable to Intrexon of $57.3 million including non-cash charges of $38.7 million
Intrexon Corporation today announced it will release third quarter 2018 financial results after the market closes on Thursday, November 8th, 2018. The Company will host a conference call that day at 5:30 PM ET to discuss the results and provide a general business update.
ActoBio Therapeutics™ Doses First Patient in Phase Ib/IIa Clinical Study of AG019 for the Treatment of Type 1 Diabetes
A unique approach to induce immune tolerance using specifically targeted and designed ActoBiotics® Lactococcus lactis engineered to express therapeutic agents.
Establishing itself as Intrexon Bioinformatics Germany GmbH (IBG)
Ziopharm to Host Conference Call at 8 a.m.
Microbial Fermentation of Cannabinoids Provides Advantages over Plant-Based Extraction
Ticker symbol to remain "XON"
Intrexon Corporation will host a call today to provide a general update and highlight recent business developments, as well as provide select preliminary and unaudited second quarter results.
Intrexon Corporation announced Robert Walsh, Senior Vice President, Energy and Fine Chemicals Platforms, will present at the Jefferies 2018 Global Industrials Conference in New York City on Tuesday, August 7, 2018 at 8:00 am Eastern.
Oxitec, Ltd. announced it is entering into a cooperative agreement with the Bill & Melinda Gates Foundation ("BMGF") to develop a new strain of Oxitec's self-limiting Friendly(TM) Mosquitoes to combat a mosquito species that spreads malaria in the Western Hemisphere.
Intrexon Corporation announced the isolation and recombinant expression of a novel gene from the opium poppy (Papaver somniferum) encoding the enzyme, thebaine synthase.
Milestone represents the first ever triple effector gene therapy for heart failure
Intrexon Corporation announced it will release first quarter 2018 financial results after the market closes on Thursday, May 10th, 2018.